Anupama Atluri, MD
Psychiatry · Baton Rouge, LANPI 1497963151
Payments from drug & device makers
Across 281 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$693
- Sunovion Pharmaceuticals Inc.$535
- Corium, LLC$490
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$363
- Indivior Inc.$324
- Otsuka America Pharmaceutical, Inc.$313
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,44497%
- Education$1213%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $693 |
| Sunovion Pharmaceuticals Inc. | 38 | $535 |
| Corium, LLC | 28 | $490 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $363 |
| Indivior Inc. | 18 | $324 |
| Otsuka America Pharmaceutical, Inc. | 17 | $313 |
| Alkermes, Inc. | 9 | $266 |
| Johnson & Johnson | 13 | $233 |
| Shire North American Group Inc | 19 | $186 |
| Teva Pharmaceuticals USA, Inc. | 11 | $185 |
| Bausch Health US, LLC | 8 | $133 |
| Lundbeck LLC | 7 | $125 |
| Vanda Pharmaceuticals Inc. | 6 | $123 |
| Avanir Pharmaceuticals, Inc. | 8 | $117 |
| Neurocrine Biosciences, Inc. | 6 | $105 |
| Eisai Inc. | 4 | $74 |
| Acadia Pharmaceuticals Inc | 4 | $66 |
| E.r. Squibb & Sons, L.L.C. | 2 | $52 |
| Almatica Pharma LLC | 2 | $43 |
| Neos Therapeutics, LP | 2 | $40 |
| Ironshore Pharmaceuticals Inc. | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $17 |
| Tris Pharma Inc | 1 | $17 |
| Orexo US, Inc. | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $14 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$440
How this compares
$4,565 in reported general payments places this provider in the 85th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 56 | $185,705 |
| IngrezzaValbenazine Tosylate | 18 | $151,568 |
| Abilify MaintenaAripiprazole | 29 | $80,994 |
| FanaptIloperidone | 11 | $70,709 |
| AristadaAripiprazole Lauroxil | 18 | $58,882 |
| PerserisRisperidone | 14 | $38,586 |
| CaplytaLumateperone Tosylate | 11 | $20,222 |
| TrintellixVortioxetine Hydrobromide | 26 | $12,396 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $7,767 |
| Clozapine | 82 | $6,281 |
| Aripiprazole | 202 | $6,100 |
| Quetiapine Fumarate | 586 | $5,917 |
| Lisdexamfetamine Dimesylate | 19 | $4,728 |
| Divalproex Sodium ErDivalproex Sodium | 111 | $4,443 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 98 | $3,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $233 | $185,70556 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $105 | $151,56818 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $313 | $80,99429 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $123 | $70,70911 claims |
| Alkermes, Inc.Aristada | $266 | $58,88218 claims |
| Indivior Inc.Perseris | $324 | $38,58614 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $363 | $20,22211 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $693 | $20,16347 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Baton Rouge
- Larry WarnerBaton Rouge$495K
- Abdul KhanBaton Rouge$156K
- Donna FargasonBaton Rouge$11K
- Aniedi UdofaBaton Rouge$9K
- Sudheera RachamalluBaton Rouge$7K
- Jason BoudreauxBaton Rouge$5K
- Kashinath YadalamLake Charles$3.8M
- Guy BrannonShreveport$1.4M
- Patrick HayesLake Charles$853K
- Maria CruseThibodaux$522K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.